| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 1982 Oxford University Press
research-article |
The Effects of Early Treatment, Lead Time and Length Bias on the Mortality Experienced by Cases Detected by Screening
Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, Mass. 02115, USA and the Division of Biostatistics and Epidemiology, Sidney Farber Cancer Institute Boston, Mass
Morrison, A (Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA). The effects of early treatment, lead time and length bias on the mortality experienced by cases detected by screening.International Journal of Epidemiology 1982, 11: 261–267.
This paper describes a means of analysing the effects that the benefit of early treatment, lead time and length-biased sampling (and other forms of prognostic selection bias) have on the mortality rate of cases detected in screening programmes. Both benefit and lead time reduce the mortality rate of screen-detected cases. A beneficial effect of early treatment will lead to a decrease in the number of deaths, the numerator of the rate. The amount of person-time among screen-detected cases, the denominator, is increased by early diagnosis as a result of screening (lead time) as well as by prolongation of life due to early treatment. The numbers of cases experiencing benefit and lead time can be estimated by comparisons of the numbers of deaths and numbers of diagnosed cases between the entire screened population, from which the series of screen-detected cases is drawn, and an other-wise comparable unscreened population. Benefit and lead time, as reflected in these numbers, can be removed from the mortality rate of cases detected by screening. The effects of benefit or lead time on prognosis then can be assessed by comparing the observed mortality rate of screen-detected cases to the rates with benefit or lead time removed. Prognostic selection bias (a tendency of screen-detected cases to be relatively benign or relatively malignant) can be evaluated by comparing the case-mortality rate, with both benefit and lead time removed, to the mortality rate of cases in an unscreened population. The relationships described are illustrated with data from a breast cancer screening programme.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. S. Mandelblatt and R. Silliman Hanging in the Balance: Making Decisions About the Benefits and Harms of Breast Cancer Screening Among the Oldest Old Without a Safety Net of Scientific Evidence J. Clin. Oncol., February 1, 2009; 27(4): 487 - 490. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Dong, D. A. Berry, T. B. Bevers, S.-W. Kau, L. Hsu, R. L. Theriault, and Y. Shen Prognostic Role of Detection Method and Its Relationship with Tumor Biomarkers in Breast Cancer: The University of Texas M. D. Anderson Cancer Center Experience Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1096 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Bach Response to "CT screening for lung cancer: update 2007". Oncologist, May 1, 2008; 13(5): 608 - 609. [Full Text] [PDF]
|
|
|
|
|
|
C. I. Henschke and D. F. Yankelevitz In Reply Oncologist, May 1, 2008; 13(5): 610 - 612. [Full Text] [PDF]
|
|
|
|
|
|
C. I. Henschke and D. F. Yankelevitz CT Screening for Lung Cancer: Update 2007 Oncologist, January 1, 2008; 13(1): 65 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Holford, K. A. Cronin, A. B. Mariotto, and E. J. Feuer Chapter 4: Changing Patterns in Breast Cancer Incidence Trends J Natl Cancer Inst Monographs, October 1, 2006; 2006(36): 19 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Kujan, A.-M. Glenny, J. Duxbury, N. Thakker, and P. Sloan Evaluation of Screening Strategies for Improving Oral Cancer Mortality: A Cochrane Systematic Review J Dent Educ., February 1, 2005; 69(2): 255 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schaufelberger, K. Swedberg, M. Koster, M. Rosen, and A. Rosengren Decreasing one-year mortality and hospitalization rates for heart failure in Sweden: Data from the Swedish Hospital Discharge Registry 1988 to 2000 Eur. Heart J., February 2, 2004; 25(4): 300 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Sunshine and K. E. Applegate Technology Assessment for Radiologists Radiology, February 1, 2004; 230(2): 309 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Levy, S. Kenchaiah, M. G. Larson, E. J. Benjamin, M. J. Kupka, K. K.L. Ho, J. M. Murabito, and R. S. Vasan Long-Term Trends in the Incidence of and Survival with Heart Failure N. Engl. J. Med., October 31, 2002; 347(18): 1397 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Jakes, S. Duffy, F. Ng, F Gao, and E. Ng Mammographic parenchymal patterns and risk of breast cancer at and after a prevalence screen in Singaporean women Int. J. Epidemiol., February 1, 2000; 29(1): 11 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Senni, C. M. Tribouilloy, R. J. Rodeheffer, S. J. Jacobsen, J. M. Evans, K. R. Bailey, and M. M. Redfield Congestive Heart Failure in the Community: Trends in Incidence and Survival in a 10-Year Period Arch Intern Med, January 11, 1999; 159(1): 29 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Jacobsen, S. K. Katusic, E. J. Bergstralh, J. E. Oesterling, D. Ohrt, G. G. Klee, C. G. Chute, and M. M. Lieber Incidence of Prostate Cancer Diagnosis in the Eras Before and After Serum Prostate-Specific Antigen Testing JAMA, November 8, 1995; 274(18): 1445 - 1449. [Abstract] [PDF]
|
|
|
|
 |
|
 R. D Etzioni, R. J Connor, P. C Prorok, and S. G Self Design and analysis of cancer screening trials Statistical Methods in Medical Research, March 1, 1995; 4(1): 3 - 17. [Abstract] [PDF]
|
|
|
|
|
|
J. V. Selby and G. D. Friedman Sigmoidoscopy in the Periodic Health Examination of Asymptomatic Adults JAMA, January 27, 1989; 261(4): 594 - 601. [Abstract] [PDF]
|
|